XML 36 R27.htm IDEA: XBRL DOCUMENT
v3.23.1

Segment Reporting | 12 Months Ended
--- | ---
Dec. 31, 2022
Segment Reporting [Abstract] |
Segment Reporting | Segment Reporting The Company has three operating segments, Health Care Benefits, Health Services and Pharmacy & Consumer Wellness, as well as a Corporate/Other segment. The Company’s segments maintain separate financial information, and the CODM evaluates the segments’ operating results on a regular basis in deciding how to allocate resources among the segments and in assessing segment performance. The CODM evaluates the performance of the Company’s segments based on adjusted operating income. Adjusted operating income is defined as operating income (GAAP measure) excluding the impact of amortization of intangible assets and other items, if any, that neither relate to the ordinary course of the Company’s business nor reflect the Company’s underlying business performance. Effective for the first quarter of 2023, adjusted operating income also excludes the impact of net realized capital gains or losses. See the reconciliation of consolidated operating income (GAAP measure) to consolidated adjusted operating income below for further context regarding the items excluded from operating income in determining adjusted operating income. The Company uses adjusted operating income as its principal measure of segment performance as it enhances the Company’s ability to compare past financial performance with current performance and analyze underlying business performance and trends. Non-GAAP financial measures the Company discloses, such as consolidated adjusted operating income, should not be considered a substitute for, or superior to, financial measures determined or calculated in accordance with GAAP. Segment financial information for the years ended December 31, 2022, 2021 and 2020 has been recast, as applicable, to reflect the following items, the impact of which are reflected in the “Adjustments” lines of the table below: •The realignment of the Company’s segments to correspond with changes made to its operating model as described in Note 1 “Significant Accounting Policies,” including the discontinuance of the former Maintenance Choice segment reporting practice as described in Note (1) of the table below. •The exclusion of the impact of net realized capital gains or losses from adjusted operating income, as described above. •The impact of the adoption of the long-duration insurance accounting standard, which the Company adopted on January 1, 2023 using a modified retrospective transition method as of January 1, 2021, as described in Note 8 “Other Insurance Liabilities and Separate Accounts.”
| Year Ended December 31, 2022
In millions | Health Care Benefits |  | Health Services |  | Pharmacy & Consumer Wellness |  | Corporate/ Other |  | Intersegment Eliminations (1) |  | Consolidated Totals
Revenues, as previously reported | $ | 91,409 |  |  | $ | 169,236 |  |  | $ | 106,594 |  |  | $ | 530 |  |  | $ | (45,302) |  |  | $ | 322,467 |
Adjustments | (59) |  |  | 340 |  |  | 2,002 |  |  | — |  |  | (2,283) |  |  | — |
Revenues, as adjusted | $ | 91,350 |  |  | $ | 169,576 |  |  | $ | 108,596 |  |  | $ | 530 |  |  | $ | (47,585) |  |  | $ | 322,467 |
Adjusted operating income (loss), as previously reported | $ | 5,984 |  |  | $ | 7,356 |  |  | $ | 6,705 |  |  | $ | (1,785) |  |  | $ | (728) |  |  | $ | 17,532 |
Adjustments | 354 |  |  | (575) |  |  | (174) |  |  | 172 |  |  | 728 |  |  | 505 |
Adjusted operating income (loss), as adjusted | $ | 6,338 |  |  | $ | 6,781 |  |  | $ | 6,531 |  |  | $ | (1,613) |  |  | $ | — |  |  | $ | 18,037 |
| Year Ended December 31, 2021
In millions | Health Care Benefits |  | Health Services |  | Pharmacy & Consumer Wellness |  | Corporate/ Other |  | Intersegment Eliminations (1) |  | Consolidated Totals
Revenues, as previously reported | $ | 82,186 |  |  | $ | 153,022 |  |  | $ | 100,105 |  |  | $ | 721 |  |  | $ | (43,923) |  |  | $ | 292,111 |
Adjustments | (67) |  |  | 870 |  |  | 1,515 |  |  | — |  |  | (2,318) |  |  | — |
Revenues, as adjusted | $ | 82,119 |  |  | $ | 153,892 |  |  | $ | 101,620 |  |  | $ | 721 |  |  | $ | (46,241) |  |  | $ | 292,111 |
Adjusted operating income (loss), as previously reported | $ | 5,012 |  |  | $ | 6,859 |  |  | $ | 7,623 |  |  | $ | (1,471) |  |  | $ | (711) |  |  | $ | 17,312 |
Adjustments | 98 |  |  | (367) |  |  | (363) |  |  | (164) |  |  | 711 |  |  | (85) |
Adjusted operating income (loss), as adjusted | $ | 5,110 |  |  | $ | 6,492 |  |  | $ | 7,260 |  |  | $ | (1,635) |  |  | $ | — |  |  | $ | 17,227 |
| Year Ended December 31, 2020
In millions | Health Care Benefits |  | Health Services |  | Pharmacy & Consumer Wellness |  | Corporate/ Other |  | Intersegment Eliminations (1) |  | Consolidated Totals
Revenues, as previously reported | $ | 75,467 |  |  | $ | 141,938 |  |  | $ | 91,198 |  |  | $ | 426 |  |  | $ | (40,323) |  |  | $ | 268,706 |
Adjustments | (58) |  |  | (584) |  |  | 2,381 |  |  | — |  |  | (1,739) |  |  | — |
Revenues, as adjusted | $ | 75,409 |  |  | $ | 141,354 |  |  | $ | 93,579 |  |  | $ | 426 |  |  | $ | (42,062) |  |  | $ | 268,706 |
Adjusted operating income (loss), as previously reported | $ | 6,188 |  |  | $ | 5,688 |  |  | $ | 6,146 |  |  | $ | (1,306) |  |  | $ | (708) |  |  | $ | 16,008 |
Adjustments | (53) |  |  | (560) |  |  | (134) |  |  | (13) |  |  | 708 |  |  | (52) |
Adjusted operating income (loss), as adjusted | $ | 6,135 |  |  | $ | 5,128 |  |  | $ | 6,012 |  |  | $ | (1,319) |  |  | $ | — |  |  | $ | 15,956 |
_____________________________________________ (1)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment. Prior to January 1, 2023, intersegment adjusted operating income eliminations occurred when members of the Health Services segment's clients enrolled in Maintenance Choice elected to pick up maintenance prescriptions at one of the Company’s retail pharmacies instead of receiving them through the mail. When this occurred, both the Health Services and Pharmacy & Consumer Wellness segments recorded the adjusted operating income on a stand-alone basis. Effective January 1, 2023, the adjusted operating income associated with such transactions is reported only in the Pharmacy & Consumer Wellness segment, therefore no adjusted operating income elimination is required. Segment financial information has been recast to reflect this change. In 2022, 2021 and 2020, revenues from the federal government accounted for 18%, 17% and 16%, respectively, of the Company’s consolidated total revenues, primarily related to contracts with CMS for coverage of Medicare-eligible individuals within the Health Care Benefits segment. The following is a reconciliation of financial measures of the Company’s segments to the consolidated totals:
In millions | Health Care Benefits |  | Health Services (1) |  | Pharmacy & Consumer Wellness |  | Corporate/ Other |  | Intersegment Eliminations (2) |  | Consolidated Totals
2022: |  |  |  |  |  |  |  |  |  |  |
Revenues from external customers | $ | 90,798 |  |  | $ | 157,968 |  |  | $ | 72,739 |  |  | $ | 124 |  |  | $ | — |  |  | $ | 321,629 |
Intersegment revenues | 76 |  |  | 11,608 |  |  | 35,901 |  |  | — |  |  | (47,585) |  |  | — |
Net investment income (loss) | 476 |  |  | — |  |  | (44) |  |  | 406 |  |  | — |  |  | 838 |
Total revenues | 91,350 |  |  | 169,576 |  |  | 108,596 |  |  | 530 |  |  | (47,585) |  |  | 322,467 |
Adjusted operating income (loss) | 6,338 |  |  | 6,781 |  |  | 6,531 |  |  | (1,613) |  |  | — |  |  | 18,037 |
Depreciation and amortization | 1,579 |  |  | 519 |  |  | 1,889 |  |  | 237 |  |  | — |  |  | 4,224 |
2021: |  |  |  |  |  |  |  |  |  |  |
Revenues from external customers | 81,457 |  |  | 143,912 |  |  | 65,418 |  |  | 125 |  |  | — |  |  | 290,912 |
Intersegment revenues | 76 |  |  | 9,980 |  |  | 36,185 |  |  | — |  |  | (46,241) |  |  | — |
Net investment income | 586 |  |  | — |  |  | 17 |  |  | 596 |  |  | — |  |  | 1,199 |
Total revenues | 82,119 |  |  | 153,892 |  |  | 101,620 |  |  | 721 |  |  | (46,241) |  |  | 292,111 |
Adjusted operating income (loss) | 5,110 |  |  | 6,492 |  |  | 7,260 |  |  | (1,635) |  |  | — |  |  | 17,227 |
Depreciation and amortization | 1,811 |  |  | 505 |  |  | 1,955 |  |  | 215 |  |  | — |  |  | 4,486 |
2020: |  |  |  |  |  |  |  |  |  |  |
Revenues from external customers | 74,871 |  |  | 131,936 |  |  | 60,990 |  |  | 111 |  |  | — |  |  | 267,908 |
Intersegment revenues | 55 |  |  | 9,418 |  |  | 32,589 |  |  | — |  |  | (42,062) |  |  | — |
Net investment income | 483 |  |  | — |  |  | — |  |  | 315 |  |  | — |  |  | 798 |
Total revenues | 75,409 |  |  | 141,354 |  |  | 93,579 |  |  | 426 |  |  | (42,062) |  |  | 268,706 |
Adjusted operating income (loss) | 6,135 |  |  | 5,128 |  |  | 6,012 |  |  | (1,319) |  |  | — |  |  | 15,956 |
Depreciation and amortization | 1,832 |  |  | 532 |  |  | 1,881 |  |  | 196 |  |  | — |  |  | 4,441 |
_____________________________________________ (1)Total revenues of the Health Services segment include approximately $12.6 billion, $11.6 billion and $10.9 billion of retail co-payments for 2022, 2021 and 2020, respectively. See Note 1 ‘‘Significant Accounting Policies’’ for additional information about retail co-payments. (2)Intersegment revenue eliminations relate to intersegment revenue generating activities that occur between the Health Care Benefits segment, the Health Services segment, and/or the Pharmacy & Consumer Wellness segment. The following is a reconciliation of consolidated operating income to adjusted operating income for the years ended December 31, 2022, 2021 and 2020:
In millions | 2022 |  | 2021 |  | 2020
Operating income (GAAP measure) | $ | 7,954 |  |  | $ | 13,310 |  |  | $ | 13,911 |
Amortization of intangible assets (1) | 1,785 |  |  | 2,233 |  |  | 2,341 |
Net realized capital (gains) losses (2) | 320 |  |  | (176) |  |  | (52) |
Office real estate optimization charges (3) | 117 |  |  | — |  |  | — |
Gain on divestiture of subsidiaries (4) | (475) |  |  | — |  |  | (269) |
Opioid litigation charges (5) | 5,803 |  |  | — |  |  | — |
Loss on assets held for sale (6) | 2,533 |  |  | — |  |  | — |
Acquisition-related integration costs (7) | — |  |  | 132 |  |  | 332 |
Store impairments (8) | — |  |  | 1,358 |  |  | — |
Goodwill impairment (9) | — |  |  | 431 |  |  | — |
Acquisition purchase price adjustment outside of measurement period (10) | — |  |  | (61) |  |  | — |
Receipt of fully reserved ACA risk corridor receivable (11) | — |  |  | — |  |  | (307) |
Adjusted operating income | $ | 18,037 |  |  | $ | 17,227 |  |  | $ | 15,956 |
_____________________________________________ (1)The Company’s acquisition activities have resulted in the recognition of intangible assets as required under the acquisition method of accounting which consist primarily of trademarks, customer contracts/relationships, covenants not to compete, technology, provider networks and value of business acquired. Definite-lived intangible assets are amortized over their estimated useful lives and are tested for impairment when events indicate that the carrying value may not be recoverable. The amortization of intangible assets is reflected in the Company’s GAAP consolidated statements of operations in operating expenses within each segment. Although intangible assets contribute to the Company’s revenue generation, the amortization of intangible assets does not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Additionally, intangible asset amortization expense typically fluctuates based on the size and timing of the Company’s acquisition activity. Accordingly, the Company believes excluding the amortization of intangible assets enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. Intangible asset amortization excluded from the related non-GAAP financial measure represents the entire amount recorded within the Company’s GAAP financial statements, and the revenue generated by the associated intangible assets has not been excluded from the related non-GAAP financial measure. Intangible asset amortization is excluded from the related non-GAAP financial measure because the amortization, unlike the related revenue, is not affected by operations of any particular period unless an intangible asset becomes impaired or the estimated useful life of an intangible asset is revised. (2)The Company’s net realized capital gains and losses arise from various types of transactions, primarily in the course of managing a portfolio of assets that support the payment of insurance liabilities. Net realized capital gains and losses are reflected in the consolidated statements of operations in net investment income within each segment. These capital gains and losses are the result of investment decisions, market conditions and other economic developments that are unrelated to the performance of the Company’s business, and the amount and timing of these capital gains and losses do not directly relate to the underwriting of the Company’s insurance products, the services performed for the Company’s customers or the sale of the Company’s products or services. Accordingly, the Company believes excluding net realized capital gains and losses enhances the Company’s and investors’ ability to compare the Company’s past financial performance with its current performance and to analyze underlying business performance and trends. (3)In 2022, the office real estate optimization charges primarily relate to the abandonment of leased real estate and the related right-of-use assets and property and equipment in connection with the planned reduction of corporate office real estate space in response to the Company’s new flexible work arrangement. The office real estate optimization charges are reflected in the Company’s GAAP consolidated statement of operations in operating expenses within the Health Care Benefits, Corporate/Other and Health Services segments. (4)In 2022, the gain on divestiture of subsidiaries represents the pre-tax gain on the sale of bswift, which the Company sold in November 2022, and the pre-tax gain on the sale of PayFlex, which the Company sold in June 2022. In 2020, the gain on divestiture of subsidiary represents the pre-tax gain on the sale of the Workers’ Compensation business, which the Company sold in July 2020. The gains on divestitures are reflected as a reduction of operating expenses in the Company’s GAAP consolidated statements of operations within the Health Care Benefits segment. (5)In 2022, the opioid litigation charges relate to agreements to resolve substantially all opioid claims against the Company by certain states and governmental entities. The opioid litigation charges are reflected within the Corporate/Other segment. (6)In 2022, the loss on assets held for sale relates to the LTC reporting unit within the Pharmacy & Consumer Wellness segment. The Company continually evaluates its portfolio for non-strategic assets. The Company determined that its LTC business was no longer a strategic asset and during the third quarter of 2022 committed to a plan to sell the LTC business. As of September 30, 2022, the LTC business met the criteria for held-for-sale accounting and its net assets were accounted for as assets held for sale. The carrying value of the LTC business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the third quarter of 2022. As of December 31, 2022, the net assets of the LTC business continued to meet the criteria for held-for-sale accounting and during the fourth quarter of 2022, an incremental loss on assets held for sale was recorded to write down the carrying value of the LTC business to its estimated fair value less costs to sell. During 2022, the loss on assets held for sale also relates to the Commercial Business reporting unit within the Health Care Benefits segment. In March 2022, the Company reached an agreement to sell its Thailand business, which was included in the Commercial Business reporting unit. At that time, a portion of the Commercial Business goodwill was specifically allocated to the Thailand business. The net assets of the Thailand business were accounted for as assets held for sale at March 31, 2022. The carrying value of the Thailand business was determined to be greater than its estimated fair value less costs to sell and a loss on assets held for sale was recorded during the first quarter of 2022. The sale of the Thailand business closed in the second quarter of 2022, and the ultimate loss on the sale was not material. (7)In 2021 and 2020, acquisition-related integration costs relate to the acquisition of Aetna. The acquisition-related integration costs are reflected in the Company’s GAAP consolidated statements of operations in operating expenses within the Corporate/Other segment. (8)In 2021, the store impairment charge relates to the write down of operating lease right-of-use assets and property and equipment in connection with the planned closure of approximately 900 retail stores between 2022 and 2024. The store impairment charge is reflected within the Pharmacy & Consumer Wellness segment. (9)In 2021, the goodwill impairment charge relates to an impairment of the remaining goodwill of the LTC reporting unit within the Pharmacy & Consumer Wellness segment. (10)In 2021, the Company received $61 million related to a purchase price working capital adjustment for an acquisition completed during the first quarter of 2020. The resolution of this matter occurred subsequent to the acquisition accounting measurement period and is reflected in the Company’s GAAP consolidated statement of operations as a reduction of operating expenses within the Health Care Benefits segment. (11)In 2020, the Company received $313 million owed to it under the ACA’s risk corridor program that was previously fully reserved for as payment was uncertain. After considering offsetting items such as the ACA’s minimum MLR rebate requirements and premium taxes, the Company recognized pre-tax income of $307 million in the Company’s GAAP consolidated statement of operations within the Health Care Benefits segment.

X
- References No definition available. + Details
Name: | us-gaap_SegmentReportingAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The entire disclosure for reporting segments including data and tables. Reportable segments include those that meet any of the following quantitative thresholds a) it's reported revenue, including sales to external customers and intersegment sales or transfers is 10 percent or more of the combined revenue, internal and external, of all operating segments b) the absolute amount of its reported profit or loss is 10 percent or more of the greater, in absolute amount of 1) the combined reported profit of all operating segments that did not report a loss or 2) the combined reported loss of all operating segments that did report a loss c) its assets are 10 percent or more of the combined assets of all operating segments. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 31 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8924-108599 Reference 2: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 34 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8981-108599 Reference 3: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (a) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 4: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 40 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9031-108599 Reference 5: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (f) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 6: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (e) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 7: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 26 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8844-108599 Reference 8: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 41 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9038-108599 Reference 9: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 32 -Subparagraph (d) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8933-108599 Reference 10: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 22 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8736-108599 Reference 11: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 42 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e9054-108599 Reference 12: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 15 -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8657-108599 Reference 13: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -SubTopic 10 -Section 50 -Paragraph 21 -Subparagraph (b) -URI https://asc.fasb.org/extlink&oid=126901519&loc=d3e8721-108599 Reference 14: http://www.xbrl.org/2003/role/disclosureRef -Publisher FASB -Name Accounting Standards Codification -Topic 280 -URI https://asc.fasb.org/topic&trid=2134510 + Details
Name: | us-gaap_SegmentReportingDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration